HomeProductsBioactive CompoundsGPCR & G Protein TargetsProstaglandin ReceptorBimatoprost
Chemical structure of CAS 155206-00-1

Bimatoprost

In Stock•Starting at $15 for 5 mg•Purity ≥ 97%
CAS No.155206-00-1
MDL No.MFCD03411999
MFC25H37NO4
MW415.60
InChI KeyAQOKCDNYWBIDND-FTOWTWDKSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg98%$15In Stock
50 mg98%$59In Stock
100 mg98%$97In Stock
250 mg98%$165In Stock
500 mg98%$276In Stock
1 g98%$423In Stock
5 g97%$1052In Stock
10 g97%$1982In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Bimatoprost is a monocarboxylic acid amide with roles as an antiglaucoma drug and an antihypertensive agent.

CAS No.155206-00-1
Product NameBimatoprost

Biological Targets

PTGFR

Associated Conditions

Vitiligo·alopecia areata·androgenetic alopecia·ocular hypertension·hypotrichosis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics • Vol. 20, Issue 4 • 2004
PMID: 15321024DOI: 10.1089/1080768041725344

Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.

Ophthalmology • Vol. 111, Issue 9 • 2004
PMID: 15350319DOI: 10.1016/j.ophtha.2004.02.006

Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).

The Journal of pharmacology and experimental therapeutics • Vol. 305, Issue 2 • 2003
PMID: 12606640DOI: 10.1124/jpet.102.047837

Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics • Vol. 19, Issue 1 • 2003
PMID: 12648303DOI: 10.1089/108076803762718105

Documentation

Similar Products